183 related articles for article (PubMed ID: 33590279)
1. Liquid biomarkers in active surveillance.
Dall'Era M
World J Urol; 2022 Jan; 40(1):21-26. PubMed ID: 33590279
[TBL] [Abstract][Full Text] [Related]
2. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
3. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
4. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
[TBL] [Abstract][Full Text] [Related]
5. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
6. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
7. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
8. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS;
Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404
[TBL] [Abstract][Full Text] [Related]
9. Serum and urinary biomarkers for detection and active surveillance of prostate cancer.
Becerra MF; Bhat A; Mouzannar A; Atluri VS; Punnen S
Curr Opin Urol; 2019 Nov; 29(6):593-597. PubMed ID: 31436568
[TBL] [Abstract][Full Text] [Related]
10. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
11. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance.
Trock BJ
Curr Opin Urol; 2014 May; 24(3):293-302. PubMed ID: 24710054
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.
Loeb S; Bruinsma SM; Nicholson J; Briganti A; Pickles T; Kakehi Y; Carlsson SV; Roobol MJ
Eur Urol; 2015 Apr; 67(4):619-26. PubMed ID: 25457014
[TBL] [Abstract][Full Text] [Related]
13. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
[TBL] [Abstract][Full Text] [Related]
14. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
15. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
17. Is Active Surveillance Too Active?
Kearns JT; Helfand BT
Curr Urol Rep; 2023 Oct; 24(10):463-469. PubMed ID: 37436691
[TBL] [Abstract][Full Text] [Related]
18. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
19. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]